These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 39084830)

  • 1. Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.
    Inzucchi SE; Arai AE
    J Am Coll Cardiol; 2024 Aug; 84(6):558-560. PubMed ID: 39084830
    [No Abstract]   [Full Text] [Related]  

  • 2. GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
    Hayat J; Shah NP; Agarwala A; Khan MS; Butler J
    Curr Atheroscler Rep; 2024 Aug; 26(8):341-351. PubMed ID: 38809399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GLP-1 receptor agonists : impact on diabetic kidney disease].
    Wéra M; Paquot N
    Rev Med Suisse; 2024 Aug; 20(884):1488-1491. PubMed ID: 39219391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.
    Neuen BL; Solomon SD
    J Am Coll Cardiol; 2024 Aug; 84(8):709-711. PubMed ID: 39142724
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.
    Elnour AA; Al Hajri N; El Khidir IY; AlAmoodi A; Ahmed SA; Sadeq A
    Curr Diabetes Rev; 2020; 16(8):820-832. PubMed ID: 32442089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists.
    Vezza T; Víctor VM
    Am J Cardiovasc Drugs; 2024 Jul; 24(4):505-507. PubMed ID: 38748390
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 9. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
    Scheen AJ
    Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
    Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
    Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tip of the iceberg: Will GLP-1 receptor agonists unintentionally contribute to titanic cardiovascular events in certain individuals?
    Arena R; Pronk NP; Lavie CJ
    Curr Probl Cardiol; 2024 Aug; 49(8):102676. PubMed ID: 38795802
    [No Abstract]   [Full Text] [Related]  

  • 13. Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.
    Patoulias D; Papadopoulos C; Kassimis G; Karagiannis A; Doumas M
    Am J Cardiol; 2021 Nov; 159():143-146. PubMed ID: 34497008
    [No Abstract]   [Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.
    Salem AM; Bain SC; Obaid DR
    Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526
    [No Abstract]   [Full Text] [Related]  

  • 15. [Heart and diabetes : What is the importance of GLP-1 receptor agonists in cardiology?].
    Moellmann J; Lehrke M
    Herz; 2022 Oct; 47(5):434-441. PubMed ID: 35857081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.
    Hosseinpour A; Sood A; Kamalpour J; Zandi E; Pakmehr S; Hosseinpour H; Sood A; Agrawal A; Gupta R
    Clin Cardiol; 2024 Jul; 47(7):e24314. PubMed ID: 38953365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [GLP-1 receptor agonists in type 2 diabetes : paradoxical real-life underuse in patients with atherosclerotic cardiovascular disease].
    Scheen A
    Rev Med Liege; 2024 Mar; 79(3):146-151. PubMed ID: 38487908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
    Marx N; Husain M; Lehrke M; Verma S; Sattar N
    Circulation; 2022 Dec; 146(24):1882-1894. PubMed ID: 36508493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The early use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk].
    Nardi F; Di Fusco SA; Spinelli A; Aquilani S; Riccio C; Caldarola P; De Luca L; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Apr; 24(4):285-292. PubMed ID: 36971172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.